{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:35:03Z","timestamp":1782484503597,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.canlet.2020.03.020","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T19:49:06Z","timestamp":1585079346000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma"],"prefix":"10.1016","volume":"480","author":[{"given":"Lun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Rastgoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Pourabdollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad","family":"Zacksenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2020.03.020_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2020.03.020_bib2","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","article-title":"A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma","volume":"112","author":"Kirshner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.03.020_bib3","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1091\/mbc.e05-12-1183","article-title":"Myristoylated, alanine-rich C-kinase substrate phosphorylation regulates growth cone adhesion and pathfinding","volume":"17","author":"Gatlin","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2020.03.020_bib4","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1158\/0008-5472.CAN-08-4783","article-title":"Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression","volume":"69","author":"Micallef","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.03.020_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2008.01.029","article-title":"MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells","volume":"314","author":"Rombouts","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2020.03.020_bib6","doi-asserted-by":"crossref","first-page":"72021","DOI":"10.18632\/oncotarget.18894","article-title":"MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer","volume":"8","author":"Dorris","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2009.03.077","article-title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells","volume":"383","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2020.03.020_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10555-017-9709-6","article-title":"Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers","volume":"36","author":"Fong","year":"2017","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.canlet.2020.03.020_bib9","doi-asserted-by":"crossref","first-page":"37649","DOI":"10.18632\/oncotarget.8726","article-title":"MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib10","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.18632\/oncotarget.14057","article-title":"MARCKS protein overexpression in inflammatory breast cancer","volume":"8","author":"Manai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib11","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.03.020_bib12","series-title":"Ciba Foundation Symposium","first-page":"145","article-title":"Calmodulin and protein kinase C cross-talk: the MARCKS protein is an actin filament and plasma membrane cross-linking protein regulated by protein kinase C phosphorylation and by calmodulin","author":"Nairn","year":"1992"},{"key":"10.1016\/j.canlet.2020.03.020_bib13","doi-asserted-by":"crossref","first-page":"40982","DOI":"10.1074\/jbc.M105614200","article-title":"MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro","volume":"276","author":"Li","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.03.020_bib14","first-page":"1","article-title":"Targeting phospho-MARCKS overcomes drug resistance and induces antitumor activity in preclinical models of Multiple Myeloma","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2020.03.020_bib15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201408-1505OC","article-title":"Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer: mechanisms and therapeutic implications","volume":"190","author":"Chen","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2020.03.020_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.201410-1922ED","article-title":"MARCKS is marked in combating lung cancer growth and acquired resistance","volume":"190","author":"Reddy","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2020.03.020_bib17","doi-asserted-by":"crossref","first-page":"60723","DOI":"10.18632\/oncotarget.11032","article-title":"Role of micro-RNAs in drug resistance of multiple myeloma","volume":"7","author":"Abdi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-017-0538-4","article-title":"Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis","volume":"10","author":"Abdi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.03.020_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-017-0492-1","article-title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","volume":"10","author":"Rastgoo","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2020.03.020_bib20","first-page":"334","article-title":"MicroRNAs in multiple myeloma and related bone disease","volume":"3","author":"Rossi","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.canlet.2020.03.020_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/521586","article-title":"MicroRNA: important player in the pathobiology of multiple myeloma","author":"Bi","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.canlet.2020.03.020_bib22","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.18632\/oncotarget.6880","article-title":"MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc","volume":"7","author":"Saha","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-14-1437","article-title":"MiR-137 and miR-197 induce apoptosis and suppress Tumorigenicity by targeting MCL-1 in multiple Myeloma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.03.020_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0140-y","article-title":"Dysregulation of EZH2\/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS","author":"Rastgoo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2020.03.020_bib25","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1158\/1078-0432.CCR-04-2685","article-title":"Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341","volume":"11","author":"Buzzeo","year":"2005","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.03.020_bib26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/bjc.2014.164","article-title":"Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents","volume":"110","author":"Saha","year":"2014","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2020.03.020_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ncb1537","article-title":"The energy sensing LKB1-AMPK pathway regulates p27kip1phosphorylation mediating the decision to enter autophagy or apoptosis","volume":"9","author":"Liang","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2020.03.020_bib28","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCFSkp2results in p27and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.03.020_bib29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.03.020_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/carcin\/bgq033","article-title":"Epigenetic inactivation of the miR-34a in hematological malignancies","volume":"31","author":"Chim","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2020.03.020_bib32","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence","volume":"18","author":"Di Martino","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.03.020_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090005","article-title":"In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma","volume":"9","author":"Di Martino","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.03.020_bib34","first-page":"5433","article-title":"MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2","volume":"8","author":"Wu","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.canlet.2020.03.020_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18186-0","article-title":"Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment","volume":"7","author":"Zarone","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2020.03.020_bib36","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/onc.2016.510","article-title":"Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.03.020_bib37","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1038\/onc.2013.336","article-title":"A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.03.020_bib38","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.18632\/oncotarget.3827","article-title":"Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.03.020_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2020.03.020_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Mari\u00f1o","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.03.020_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2407-7-24","article-title":"E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation","volume":"7","author":"Hao","year":"2007","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2020.03.020_bib42","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1182\/blood.V124.21.5775.5775","article-title":"A phase II trial of chloroquine in combination with bortezomib and cyclophosphamide in patients with relapsed and refractory multiple myeloma","volume":"124","author":"Montanari","year":"2014","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520301452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520301452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:48:12Z","timestamp":1759592892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520301452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":41,"alternative-id":["S0304383520301452"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.03.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}